Kinase inhibitors and methods of use thereof

A method of treating a GSK3- or CK1-mediated disorder comprising administering to a subject suffering from a GSK3- or CK1-mediated disorder an effective amount of a compound of formula I:

• or a pharmaceutically acceptable salt thereof,
• wherein:
• the GSK3- or CK1-mediated disorder is a neurological disease, psychiatric disorder, cancer, or metabolic disorder;
• R1 is selected from the group consisting of optionally substituted C1-6 alkyl, optionally substituted phenyl, and optionally substituted heteroaryl;
• R2 is optionally substituted C1-6 alkyl;
• or R1 and R2 are taken together with their intervening atoms to form an optionally substituted, 3- to 7-membered, monocyclic, saturated, carbocyclyl or heterocyclyl, wherein the carbocyclyl or heterocyclyl formed by taking together R1 and R2 is optionally fused to optionally substituted phenyl or optionally substituted heteroaryl;
• R3 is selected from the group consisting of hydrogen, halogen, —CN, —NO2, optionally substituted C1-6 alkyl, optionally substituted, 3- to 6-membered, monocyclic, cycloalkyl, optionally substituted phenyl;
• ORA, —N(RB)2, and —SRA;
• each RA is independently selected from the group consisting of hydrogen and optionally substituted C1-6 alkyl;
• each RB is independently selected from the group consisting of hydrogen and optionally substituted C1-6 alkyl;
• R4a and R4b are each independently selected from the group consisting of hydrogen, halogen, and optionally substituted C1-6 alkyl;
• R5a and R5b are each independently selected from the group consisting of hydrogen, halogen, —CN, —ORA, —N(RB)2, and optionally substituted C1-6 alkyl, or R5a and R5b are taken together with their intervening atoms to form unsubstituted, 3- to 7-membered, monocyclic, saturated, carbocyclyl or heterocyclyl;
• R6a and R6b are each independently selected from the group consisting of hydrogen, halogen, and optionally substituted C1-6 alkyl;
• each instance of the heteroaryl is independently 5- or 6-membered, monocyclic heteroaryl comprising 1 to 4 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, as valency allows;
• and
• each instance of the heterocyclyl independently comprises 1 to 4 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, as valency allows.